Current indications for reduced-intensity allogeneic stem cell transplantation

This publication has 35 references indexed in Scilit:

• BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
  Blood, 2004
• Minimal GVHD following in-vitro Tcell–depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors
  Experimental Hematology, 2003
• T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions
  British Journal of Haematology, 2003
• Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen
  Experimental Hematology, 2003
• Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation
  British Journal of Haematology, 2003
• Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation
  Bone Marrow Transplantation, 2003
• Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
  Blood, 2003
• Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution
  Transplantation, 2003
• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
  Blood, 2003
• Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
  Blood, 2002